This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
<< Back to CME Activities
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event » 
Learn More & View Event »
TeleECHO Sessions
Project ECHO® is a lifelong learning and guided practice model that revolutionizes online CME courses and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct online CME courses and virtual clinics with community providers. In this way, ECHO®
allows CME providers to foster problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.
The Project ECHO® format fosters dialogue in a way most online CME courses don’t and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.
Show : Per page of 7
Using Multidisciplinary Management to Address Pathophysiologic Pathways in Paroxysmal Nocturnal Hemoglobinuria
This enduring educational activity will provide important information on the burden of Paroxysmal Nocturnal Hemoglobinuria (PNH) on patient quality of life, the pathophysiology of PNH, and the latest efficacy and safety data on existing and emerging therapeutic options.
RELEASED DATE: October 19, 2023
EXPIRATION DATE: October 26, 2024
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
Updates and Best Practices Across Malignancies:
Evaluating Therapeutic Developments and Optimizing Multidisciplinary Care in Cutaneous Squamous Cell Carcinoma
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in cutaneous squamous cell carcinoma.
RELEASED DATE: August 10, 2023
EXPIRATION DATE: August 10, 2024
Key Updates in Bispecific Antibodies in NHL Management—Unmet Needs and Opportunities for Improved Management in Later-Line Management
This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin's lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
Immune Challenges in Cancer: First-Line IO Therapy of Advanced Non-Small Cell Lung Cancer
This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pharmacists, nurse practitioners, and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
RELEASED DATE: August 15, 2023
EXPIRATION DATE: August 15, 2024
Factors Associated with Decision Making in the Second-Line Treatment of Patients with Advanced/Metastatic Gastrointestinal Cancers
This enduring educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The program aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers, and to select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.
RELEASED DATE: October 13, 2023
EXPIRATION DATE: November 28, 2024
Applying the VA Preferred Care Roadmap: Front-Line Treatment of Advanced Non-small Cell Lung Cancer
This educational activity is designed to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC. We aim to discuss both the VA oncology clinical pathways and oncology precision program to guide personalized NSCLC care; evaluate immune checkpoint monotherapy clinical findings in the front-line treatment of patients with advanced NSCLC without targetable mutations; and examine the trials data for PD-1 inhibitor/chemotherapy combinations in the front-line management of patients with advanced NSCLC and no targetable mutations.
RELEASED DATE: August 15, 2023
EXPIRATION DATE: August 15, 2024